Chronic Lymphocytic Leukemia (CLL) is a slow-progressing cancer of bone marrow and blood. U.S. FDA has approved Venetoclax, a first BCL2 inhibitor, for CLL patients with 17p chromosomal deletion who has received at least one prior therapy. This article discusses the mode of action, clinical studies, adverse effects as well as precautions recommended during Venetoclax treatment. Chronic Lymphocytic Leukemia (CLL), a slow-progressing cancer of bone marrow and blood, is one of the most common types of leukemia in adults with about 15000 new cases diagnosed every year.
Progressive accumulation of abnormal lymphocytes (a kind of White Blood Cells) is the main characteristic of CLL. CLL may disappear for some time following the treatment. Therefore, many patients have to undergo additional treatment due return of the disease. In some cases of CLL, deletion of 17p - a region on chromosome –…
